630
Participants
Start Date
June 10, 2024
Primary Completion Date
April 30, 2025
Study Completion Date
December 31, 2026
Screening of DR and DME with artificial intelligence using NeoRetina
Macula-centered eye color fundus photos will be acquired by DIAGNOS team using a non-mydriatic digital camera (without pupil dilation). After a numerical treatment, retinal images will be analyzed by NeoRetina artificial intelligence (AI) algorithm in order to find eye lesions characteristics of diabetic retinopathy (DR) and diabetic macular edema (DME). The severity of DR and DME will be graded by NeoRetina according to the ''Early Treatment Diabetic Retinopathy Study'' (ETDRS) international classification standards.
Routine ophthalmological evaluation of DR and DME
Standard of care eye examination (blind assessment) will be performed by an ophthalmologist of the CHUM in order to find lesions characteristics of diabetic retinopathy (DR) and diabetic macular edema (DME). The severity of DR and DME will be graded by the doctor according to the ''Early Treatment Diabetic Retinopathy Study'' (ETDRS) international classification standards.
Manual grading of DR and DME by CHUM ophthalmologists based on retinal photographies acquired by Diagnos
Ophthalmologists of the CHUM will revise the macula-centered eye color photos acquired by DIAGNOS in order to find lesions characteristics of diabetic retinopathy (DR) and diabetic macular edema (DME). The severity of DR and DME will be graded (blind assessment) according to the ''Early Treatment Diabetic Retinopathy Study'' (ETDRS) international classification standards.
RECRUITING
Centre hospitalier de l'Université de Montréal, Montreal
DIAGNOS Inc.
UNKNOWN
Centre hospitalier de l'Université de Montréal (CHUM)
OTHER